0: Despite recent advances in medical sciences and the development of multiple antidiabetic or antihyperlipidemic drug classes, the prevalence of diabetes mellitus and dyslipidemia and the associated risk of premature death have constantly increased in low- and medium-income countries ( Magliano et al., 2019).
1: The ever-growing treatment cost of metabolic diseases may have a huge economic impact in several parts of the world, limiting the access of patients to effective treatments.
2: In this context, the discovery of new molecules of natural origin, capable of being translated into cost-effective antidiabetic and antihyperlipidemic drugs could be important for large categories of patients, having the potential advantages of being readily available and better tolerated ( Yatoo et al., 2017).
